Welcome to Psychiatryai.com: Latest Evidence - RAISR4D

Estimated reading time for CME/CPD: 2 mins

Immune Checkpoint Dysregulation in Inflammatory Neuropathies: An Exploratory Study

AI Summary
  • Elevated expression of PDCD1, CTLA4, CD274, and CD86 observed in inflammatory neuropathies compared with healthy controls.
  • Distinct profiles between disorders: GBS shows upregulated PDCD1 and CD274; CIDP shows higher CTLA4, CD274, CD86, and CD80.
  • Findings indicate immune checkpoint pathways may contribute to IN pathogenesis and merit further investigation in larger cohorts.
Summarise with AI (MRCPsych/FRANZCP)

Muscle Nerve. 2026 Nov 18. doi: 10.1002/mus.70458. Online ahead of print.

ABSTRACT

INTRODUCTION/AIMS: Inflammatory neuropathies (IN), such as Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), are characterized by peripheral nerve injury driven by immune activation, although the precise mechanisms remain unknown. Dysregulated immune checkpoint molecules (ICMs) are known to trigger autoimmunity and inflammation; however, the role of ICMs is not well elucidated in IN. We investigated the gene expression levels of ICMs, such as programmed cell death protein-1 (PD-1) and cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), as well as their respective ligands (CD274, and CD86/CD80) in IN.

METHODS: This case-control, cross-sectional, hospital-based study included 67 patients with IN (GBS = 47, CIDP = 20) and equal number of healthy controls. Gene expression levels of PDCD1, CD274, CTLA4, CD86, and CD80 were quantified using ddPCR and correlated with the clinical and electrophysiological parameters.

RESULTS: PDCD1, CTLA4, CD274, and CD86 gene expression levels were significantly higher in IN than in healthy controls (p = 0.001, 0.017, 0.001, and 0.006, respectively). In GBS, PDCD1 and CD274 expression levels were significantly increased compared with controls (p = 0.001 and 0.003, respectively), whereas in CIDP, the expression levels of CTLA4, CD274, CD86, and CD80 were higher than in controls (p = 0.050, 0.033, 0.003, and 0.016, respectively). CTLA4, CD86, and CD80 expression levels were greater in CIDP than in GBS (p = 0.049, 0.001, and 0.014, respectively).

DISCUSSION: This study demonstrates differential expression of ICMs in GBS and CIDP. The immune checkpoint pathways may play a crucial role in the pathogenesis of inflammatory neuropathies, which warrants further exploration in larger cohorts.

PMID:43046936 | DOI:10.1002/mus.70458

Document this CPD

Share Evidence Blueprint

QR Code

Save to Google Notes

Search Google Scholar

⭐ My Revision List

close chatgpt icon
ChatGPT

Enter your request.

← →
RAISR4D CME/CPD Evidence Nodes
Swipe to navigate RAISR4D CME/CPD evidence nodes.
CME/CPD